Skip to main content
Premium Trial:

Request an Annual Quote

Nova Satra Nabs $2M Investment

NEW YORK (GenomeWeb) – Singapore-based molecular diagnostics firm Nova Satra today announced a US$2 million investment from Genting Bio Cellular, a wholly owned subsidiary of investment and management firm Genting Berhad.

The funds will be used for regulatory approvals and commercialization of Nova Satra's lead test, a noninvasive blood-based test for breast cancer, which leverages an epigenetic platform technology developed at the University of Oxford. The test relies on highly stable DNA-based targets as part of chromosomal signatures instead of unstable protein/RNA molecules that other molecular diagnostics rely on, the company said.

In conjunction with the financing, Genting Bio Cellular acquired the exclusive rights to distribute the test in Malaysia. Two directors nominated by Genting also joined Nova Satra's board.

The company said that it also intends to make available a pipeline of molecular diagnostic tests across multiple cancers.

Nova Satra CoFounder and CEO Kane Black said that the investment provides the firm with capital resources and "substantial operation support to our research, development, and commercialization program." 

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.